Summary
Oral glucose tolerance tests (1.75 g glucose/ kg ideal body weight) were performed in 29 normal subjects, 17 maturity-onset diabetics (D I) and 8 juvenile type diabetics (D II). Glucose, IRI, pancreatic and gut glucagon-like immunoreactivity (GLI) were determined at various intervals. The basal levels of pancreatic GLI in the three groups were as follows: normals: 0.33 ±0.03; D I: 0.43±0.06; and D II: 0.50±0.05 ng equiv./ml (mean±s.e.m.). After glucose, a significant decrease in pancreatic GLI was observed in the normals, whereas the diabetics showed no significant change. An increase in gut GLI was observed in all persons. The importance of the GLI levels and variations is discussed.
Article PDF
Avoid common mistakes on your manuscript.
References
Aguilar-Parada, E., Eisentraut, A.M., Unger, R.H.: Pancreatic glucagon secretion in normal and diabetic subjects. Amer. J. med. Sci.257, 415–419 (1969a).
Aguilar-Parada, E., Eisentraut, A.M., Unger, R.H.: Effects of starvation on plasma pancreatic glucagon in normal man. Diabetes18, 717–723 (1969b).
Heding, L.G.: Glucagon antibodies for the radioimmunoassay of pancreatic and gut glucagon. Paper presented at the fourth annual meeting of the European Associa 131 labelled human growth hormone of high specific activity. Nature194, 495–496 (1962).
Jørgensen, K.H., Larsen, U.D.: Purification of125I-glucagon in anion exchange chromatography. Horm. Metab. Res.4, 223–224 (1972).
Marco, J., Faloona, G.R., Unger, R.H.: Effect of endogenous intestinal glucagon-like immunoreactivity (GLI) on insulin secretion and glucose concentration in dogs. J. clin. Endocr.33, 318–375 (1971).
Moody, A. J., Heding, L.G., Markussen, J., Steenstrup,C., Sundby, F.: The connection between gut GLI and insulin releasing activity. Origin, Chemistry, Physiology and Pathophysiology of the Gastrointestinal Hormones. Ed. W. Creutzfeldt. Stuttgart-New York: F.K. Schattauer Verlag.
Müller, W.A., Faloona, G.R., Aguilar-Parada, E., Unger, R.H.: Abnormal alpha-cell function in diabetes. New Engl. J. Med.283, 109–115 (1970).
Müller, W.A., Faloona, G.R., Unger, R.H.: The effect of experimental insulin deficiency on glucagon secretion. J. clin. Invest.50, 1992–1999 (1971).
Persson, I., Gyntelberg, F., Heding, L.G., Boss-Nielsen, J.: Pancreatic glucagon-like immunoreactivity after intravenous insulin in normals and chronic-pancreatitis patients. Acta endocrin.67, 401–404 (1971).
Rasmussen, S. Munkgaard, Heding, L.G., Parbst, E., Vølund, Aa.: Glucose and insulin responses to OGTT in newlv detected diabetics and their subsequent treatment. Abs. in Diabetologia5, 428–429 (1969). Paper presented at the fifth annual meeting of the Scandinavian Society for the Study of Diabetes, Copenhagen 1969.
Sundby, F.: Abs. Seventh Congress of the International Diabetes Federation, Buenos Aires, Exerpta Medica No.209, Abstract No. 179.
Unger, R.H., Aguilar-Parada, E., Müller, W.A., Eisentraut, A.M.: Studies of pancreatic alpha-cell function in normal and diabetic subjects. J. clin. Invest.49, 837–848 (1970).
Valverde, J., Rigopoulou, D., Marco, J., Faloona, G.R., Unger, R.H.: Characterization of glucagon-like immunoreactivity (GLI). Diabetes19, 614–623 (1970).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Heding, L.G., Rasmussen, S.M. Determination of pancreatic and gut Glucagon-Like Immunoreactivity (GLI) in normal and diabetic subjects. Diabetologia 8, 408–411 (1972). https://doi.org/10.1007/BF01212168
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01212168